Recent advances in immunology have underscored the pivotal role of the transcription factor RORĪ³t in orchestrating the differentiation of Th17 cells and the consequent production of proinflammatory ...
Maplight Therapeutics Inc. has synthesized G protein-coupled receptor GPR6 inverse agonists reported to be useful for the treatment of anxiety, bipolar disorder, eating disorders, depression, ...
CRB-913 is a member of a new class of peripherally restricted CB1 inverse agonists designed to have reduced brain penetration. Pre-clinical models have shown CRB-913 to be 15-fold less brain penetrant ...
(A) GPCR agonists increase the proportion of active receptor states; inverse agonists decrease the proportion of active receptor states; and antagonists inhibit the action of other ligands. (B) In ...
Monlunabant shows significant and clinically meaningful weight loss over 16 weeks in patients with obesity and metabolic ...
CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabant SAD/MAD Phase 1 trial scheduled ...
Corbus Pharmaceuticals reports no neuropsychiatric events in CRB-913 trial, advancing to multiple ascending dose phase. Study completion projected for Q3 2025. Corbus Pharmaceuticals Holdings Inc. has ...
NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the initiation of the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback